The challenge: Atrial fibrillation (AF) is a chronic progressive disease affecting more than 700,000 people. The first line of treatment is medication, but that doesn’t prevent AF from progressing. A promising long-term solution is a minimally invasive procedure that uses two technologies developed and manufactured in Canada. CANet has brought together academic researchers, physicians and health economists in a cross-country clinical trial involving 300 patients that will simplify the procedure.
The response: The procedure uses a radiofrequency transseptal needle, made by Baylis Medical, and a cryoablation balloon catheter, made by Medtronic Canada, to destroy tiny areas in the heart that cause rapid and irregular heartbeats. Researchers believe using this procedure on individuals early in their conditions could stop AF from reoccurring later in life – preventing premature deaths and saving the health care system hundreds of millions of dollars.